A farewell message from outgoing Government Affairs Committee Chair Angus Worthing urges ACR/ARP members to advocate for the rheumatology profession.
Search results for: "infusion center"
Ethics Forum: What Are Conflicts of Interest?
Results from an ethics survey presented to attendees at the 2018 ACR/ARHP Annual Meeting highlight the complexities and challenges of assessing potential conflicts of interest.
Rheumatology Advocacy in 2019
A belated Happy New Year to my fellow advocates! Here’s your first update for 2019 on what the rheumatology community should know is going on in Washington, D.C., right now. Current Climate On Jan. 3, the 116th Congress gaveled into session with Democrats in control of the House of Representatives and Republicans still the majority in the…
Rheumatology Clinics Add Pharmacists to Care Teams, See Benefits
CHICAGO—Could the addition of a pharmacist to rheumatology care teams improve patient satisfaction, decrease staff burnout or reduce medication-related problems? Three panelists in Integrating Pharmacists into the Workforce, a session at the 2018 ACR/ARHP Annual Meeting, shared positive experiences with this interdisciplinary care model. Less Burnout, More Satisfaction Ten years ago, the Arthritis Treatment Center…
Protect Your Practice: Action Update From the ACR’s Insurance Subcommittee
Both private and academic rheumatology practices face payer challenges that put the health of their patients and their practices at risk. To make sure the rheumatologist perspective is heard by payers, “the ACR’s Insurance Subcommittee (ISC) serves as the interface between payers and our members and ACR colleagues,” explains Sean Fahey, MD, a rheumatologist in…
Congress Urged to Fix CMS Rule Distorting Part B Drug Reimbursement
LATE-BREAKING NEWS Editor’s note: The ACR praises Congressional leaders for passing today’s (2/9) sweeping spending agreement, which includes a technical provision reversing a Centers for Medicare & Medicaid Services (CMS) policy that would have linked physicians’ quality payment adjustments to Medicare Part B drug costs starting in 2019. The ACR also applauded the inclusion of…
Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?
SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…
Time & Money: Tech Investments for Rheumatology
Electronic health records, personal trackers, pedometers—all these technologies result in data, data and more data. What types of technology investments will help rheumatology practices collect and understand these data? Here are some insights into investing in technology for your practice…
Biosimilars Great Debate: To Switch or Not?
SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…
How Non-Physician Providers Can Help Your Practice
New data shows that both private and public rheumatology practices benefit financially by hiring non-physician providers (NPPs). But when should practices hire NPPs?